What Is the Role of MRD in Myeloma Maintenance Therapy?

By Blood Cancer Talks - Last Updated: May 30, 2024

In this episode of “Blood Cancer Talks,” Hira Mian, MD, MSc, of McMaster University, and Manni Mohyuddin, MBBS, of the University of Utah, join hosts Raj Chakraborty, MD; Ashwin Kishtagari, MD; and Edward Cliff, MD; to discuss maintenance therapy in multiple myeloma.

First, they outlined various clinical trials that studied the following treatment regimens:

  • Lenalidomide
  • Carfilzomib and lenalidomide
  • Lenalidomide and dexamethasone
  • Carfilzomib, lenalidomide, and dexamethasone
  • Ixazomib, lenalidomide, and dexamethasone

They also discussed measurable residual disease (MRD)-guided treatment and the secondary analysis of the GEM2014MAIN trial, which supports maintenance therapy discontinuation in patients with MRD negativity at two years.

Editorial Board